期刊文献+

心衰患者血浆儿茶酚抑素和脑钠肽水平变化及其相关性 被引量:6

Changes of plasma levels of catestatin and brain natriuretic peptide in patients with chronic heart failure and their correlation
下载PDF
导出
摘要 目的:探讨血浆儿茶酚抑素(CST)及脑钠肽(BNP)水平在慢性心力衰竭(CHF)患者中的变化及其相关性。方法:入选2014年6月-12月于我院心内科诊治的60例CHF患者为CHF组,另选择同期健康体检者60例作为正常对照组。采用酶联免疫吸附法测定两组血浆CST及BNP水平,并进行比较。直线相关分析血浆CST与BNP水平的相关性。结果:与正常对照组相比,CHF组血浆CST[(0.40±0.15)ng/L比(0.88±0.34)ng/L]及BNP[(30.84±12.56)ng/L比(678.21±120.35)ng/L]水平均显著升高(P均〈0.01)。直线相关分析显示血浆CST水平与BNP水平呈显著正相关(r=0.38,P〈0.05)。结论:儿茶酚抑素水平与最敏感的心功能指标脑钠肽水平呈显著正相关,提示其可作为诊断或排除心力衰竭的新的生化标志物。 Objective:To explore changes of plasma levels of catestatin(CST)and brain natriuretic peptide(BNP)in patients with chronic heart failure(CHF)and their correlation.Methods:A total of 60 CHF patients treated in our department of cardiology from Jun 2014 to Dec 2014 were enrolled as CHF group,another 60 healthy subjects undergoing physical examination were regarded as normal control group.Enzyme linked immunosorbent assay was used to measure plasma levels of CST and BNP in two groups,then the results were compared.Linear correlation analysis was used to analyze the correlation between plasma levels of CST and BNP.Results:Compared with normal control group,there were significant rise in plasma levels of CST [(0.40±0.15)ng/L vs.(0.88±0.34)ng/L]and BNP[(30.84±12.56)ng/L vs.(678.21±120.35)ng/L]in CHF group,P〈0.01 both.Linear correlation analysis indicated that plasma CST level was significant positively correlated with BNP level(r=0.38,P〈0.05).Conclusion:Catestatin level is significant positively correlated with the most sensitive cardiac function index—brain natriuretic peptide level,suggesting that it could be used as a new biochemical marker diagnosing or excluding heart failure.
出处 《心血管康复医学杂志》 CAS 2016年第2期145-147,共3页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 心力衰竭 利钠肽 儿茶酚抑素 Heart failure Natriuretic peptide brain Catestatin
  • 相关文献

参考文献8

  • 1Mahapatra NR. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure [J]. Cardiovasc Res, 2008, 80 (3): 330-338. 被引量:1
  • 2Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chro- mogranin a fragment is a noncompetitive nicotinic cholinergic antagonist [J]. J Clin Invest, 1997, 100 (6): 1623-1633. 被引量:1
  • 3Kriiger PG, Mahata SK, Helle KB. Catestatin (CGA344 - 364) stimulates rat mast cell release of histamine in a manner compa- rable to mastoparan and other cationic charged neuropeptides [J]. Regul Pept, 2003, 114 (1) : 29- 35. 被引量:1
  • 4O'Connor DT, Kailasam MT, Kennedy BP, et al. Early decline in the cateeholamine release-inhibitory peptide catestatin in hu- mans at genetic risk of hypertension I[J]. J Hypertens, 2002, 20 (7) .. 1335- 1345. 被引量:1
  • 5Mahata SK, Mahata M, Parmer RJ, et al. Desensitization of catecholamine release. The novel catecholamine release-inhibi-tory peptide catestatin (chromogranin a344 - 364) acts at the re- ceptor to prevent nicotinic cholinergic tolerance [J]. J Biol Chem, 1999, 274 (5): 2920-2928. 被引量:1
  • 6O'Connor DT, Cadman PE, Smiley C, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism [J]. J Clin Endocrind Metab, 2005, 90 (9): 5414 - 5425. 被引量:1
  • 7Mazza R, Gattuso A, Mannarino C, et al. Catestatin (chro- mogranin A344-364) is a novel cardiosuppressive agent: inhi- bition of isoproterenol and endotilelin signaling in the frog heart [J]. Am J Physiol Heart Circ Physiol, 2008, 295 (1) : Hl13 - H122. 被引量:1
  • 8Angelone T, Quintieri AM, Brar BK, et al. The antihypertens- ive chromogranin a peptide catestatin acts as a novel endocrine/ paracrine modulator of cardiac inotropism and lusitropism [J]. Endocrinology, 2008, 149 (10), 4780- 4793. 被引量:1

同被引文献62

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部